Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-706 vs US and EU Dupixent in Healthy Participants
NCT07358156Phase 1Recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2026
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of dupilumab in atopic dermatitis (AD) (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum serum concentration, Area under the concentration-time curve from time zero up to infinity and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07358156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358156.